Detection of activated platelets in a mouse model of carotid artery thrombosis with 18F-labeled single-chain antibodies

Nuclear Medicine and Biology

Volumn 41, Issue 3, 2014, Pages 229-237

  Ardipradja, Katie ^a,b,c,d   Yeoh, Shinn Dee ^c   Alt, Karen ^a,b   O'Keefe, Graeme ^c   Rigopoulos, Angela ^c   Howells, David W ^c   Scott, Andrew M ^c,d   Peter, Karlheinz ^b,e   Ackerman, Uwe ^c,d   Hagemeyer, Christoph E ^a,e  

^a Vascular Biotechnology Baker IDI   (Australia)

^b Atherothrombosis and Vascular Biology Laboratory   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Antibodies; PET CT; Platelets; Thrombosis

Indexed keywords

ANTIBODIES; PET/CT; PLATELETS; THROMBOSIS;

ANIMALS; BENZOATES; BLOOD COAGULATION; CAROTID ARTERY THROMBOSIS; DISEASE MODELS, ANIMAL; FEMALE; FLUORINE RADIOISOTOPES; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICE, INBRED C57BL; PLATELET ACTIVATION; POSITRON-EMISSION TOMOGRAPHY; SINGLE-CHAIN ANTIBODIES;

EID: 84893925745     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.12.006     Document Type: Article

References (49)

1. Varnava A.M., Mills P.G., Davies M.J. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002, 105:939-943.
2. Schafer A., Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008, 6:52-60.
3. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
4. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384.
5. Gawaz M., Stellos K., Langer H.F. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2008, 6:235-242.
6. von zur Muhlen C., von Elverfeldt D., Moeller J.A., Choudhury R.P., Paul D., Hagemeyer C.E., et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008, 118:258-267.
7. von Elverfeldt D., von zur Muhlen C., Wiens K., Neudorfer I., Zirlik A., Meißner M., et al. In vivo detection of activated platelets allows characterizing rupture of atherosclerotic plaques with molecular magnetic resonance imaging in mice. PLoS One 2012, 7:e45008.
8. Choudhury R.P., Fuster V., Fayad Z.A. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004, 3:913-925.
9. Choudhury R.P., Fisher E.A. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 2009, 29:983-991.
10. Nahrendorf M., Jaffer F.A., Kelly K.A., Sosnovik D.E., Aikawa E., Libby P., et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504-1511.
11. Spuentrup E., Buecker A., Katoh M., Wiethoff A.J., Parsons E.C., Botnar R.M., et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 2005, 111:1377-1382.
12. Wu A.M. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 2009, 50:2-5.
13. Bell A., Wang Z.J., Arbabi-Ghahroudi M., Chang T.A., Durocher Y., Trojahn U., et al. Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett 2010, 289:81-90.
14. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.
15. Hagemeyer C.E., zur Muhlen von C., Elverfeldt von D., Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 2009, 101:1012-1019.
16. von zur Muhlen C., Sibson N.R., Peter K., Campbell S.J., Wilainam P., Grau G.E., et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest 2008, 118:1198-1207.
17. von zur Muhlen C., Peter K., Ali Z.A., Schneider J.E., McAteer M.A., Neubauer S., et al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res 2009, 46:6-14.
18. McAteer M.A., Akhtar A.M., von zur Muhlen C., Choudhury R.P. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis 2010, 209:18-27.
19. Sureshbabu W., Mawlawi O. PET/CT imaging artifacts. J Nucl Med Technol 2005, 33:156-161.
20. Rudd J.H.F., Fayad Z.A. Imaging atherosclerotic plaque inflammation. Nat Clin Pract Cardiovasc Med 2008, 5:S11-S17.
21. Sinusas A.J., Bengel F., Nahrendorf M., Epstein F.H., Wu J.C., Villanueva F.S., et al. Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging 2008, 1:244-256.
22. Heidt T., Deininger F., Peter K., Goldschmidt J., Pethe A., Hagemeyer C.E., et al. Activated platelets in carotid artery thrombosis in mice can be selectively targeted with a radiolabeled single-chain antibody. PLoS One 2011, 6:e18446.
23. Stoll P., Bassler N., Hagemeyer C.E., Eisenhardt S.U., Chen Y.C., Schmidt R., et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007, 27:1206-1212.
24. Wang X., Hagemeyer C.E., Hohmann J.D., Leitner E., Armstrong P.C., Jia F., et al. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique noninvasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. Circulation 2012, 125:3117-3126.
25. Ta H.T., Prabhu S., Leitner E., Jia F., Elverfeldt von D., Jackson K.E., et al. Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ Res 2011, 109:365-373.
26. 3, CD41/CD61). J Pharmacol Exp Ther 2004, 308:1002-1011.
27. 18F. Nat Protoc 2006, 1:1655-1661.
28. von zur Muhlen C., von Elverfeldt D., Choudhury R.P., Ender J., Ahrens I., Schwarz M., et al. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging 2008, 7:59-67.
29. 18F] fluorobenzoate on an IBA Synthera module. J Labelled Comp Radiopharm 2011, 54:671-673.
30. Wagner C.L., Mascelli M.A., Neblock D.S., Weisman H.F., Coller B.S., Jordan R.E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996, 88:907-914.
31. Hagemeyer C.E., Peter K. Targeting the platelet integrin GPIIb/IIIa. Curr Pharm Des 2010, 16:4119-4133.
32. Smyth S.S., Tsakiris D.A., Scudder L.E., Coller B.S. Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): studies using monoclonal antibodies and beta3-null mice. Thromb Haemost 2000, 84:1103-1108.
33. Marx R.E. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004, 62:489-496.
34. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 2007, 48:304-310.
35. Langer H.F., Haubner R., Pichler B.J., Gawaz M. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 2008, 52:1-12.
36. 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging 2009, 2:331-338.
37. Bassler N., Loeffler C., Mangin P., Yuan Y., Schwarz M., Hagemeyer C.E., et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol 2007, 27:e9-e15.
38. Du X.P.X., Plow E.F.E., Frelinger A.L.A., O'Toole T.E.T., Loftus J.C.J., Ginsberg M.H.M. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991, 65:409-416.
39. Kenanova V., Wu A.M. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 2006, 3:53-70.
40. Olafsen T., Wu A.M. Antibody vectors for imaging. Semin Nucl Med 2010, 40:167-181.
41. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
42. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging 2009, 2:1213-1222.
43. Jaffer F.A., Libby P., Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1017-1024.
44. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
45. Jennings L.K. Role of platelets in atherothrombosis. Am J Cardiol 2009, 103:4-10.
46. Thim T., Hagensen M.K., Bentzon J.F., Falk E. From vulnerable plaque to atherothrombosis. J Intern Med 2008, 263:506-516.
47. Woollard K.J., Sturgeon S., Chin-Dusting J.P.F., Salem H.H., Jackson S.P. Erythrocyte hemolysis and hemoglobin oxidation promote ferric chloride-induced vascular injury. J Biol Chem 2009, 284:13110-13118.
48. Owens A.P., Lu Y., Whinna H.C., Gachet C., Fay W.P., Mackman N. Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost 2011, 9:1862-1863.
49. Day S.M., Reeve J.L., Myers D.D., Fay W.P. Murine thrombosis models. Thromb Haemost 2004, 92:486-494.